Regeneks

The Regeneks company developed the unique technique for cultivation of own regulatory T-cages allowing to receive their sufficient quantity in a short time (6–8 days). Authors of a method suggest to compensate deficit of regulatory T-cages at patients by introduction of additional quantity of own cages which are grown up by ex Vivo.

Advantages of technology are that for each patient individual medicine is made of own cells of the patient. The method is compatible to traditional methods of treatment and has no expressed ghost effects.

According to statistical data, for 2018 the number of patients with multiple sclerosis in Russia is more than 150 thousand people. The average cost of treatment by immunomodulatory medicines of the patient with multiple sclerosis costs 370 thousand rubles.

For 2018 "Regeneks" cooperates with the leading medical scientific centers, among partners:

• Russian national research medical university of N.I. Pirogov,
• Scientific center of neurology of the Russian Academy of Medical Science,
• Research institute of rheumatology of the Russian Academy of Medical Science.

2012: Resident Skolkovo and receiving grant

In 2012 the Project of scientific research on multiple sclerosis provided by staff of Department of cellular technologies and regenerative medicine to Skolkovo Foundation got approval of Expert advice Skolkovo, and the company "Regeneks" was accepted in number of residents. Also the grant for a period of 6 months for submission of the patent, carrying out marketing researches and pilot tests of multiple sclerosis and RTPH was received. This first grant of Skolkovo Foundation allowed to help 9 patients.

2011: Foundation of the company

"Регенекс" – the biotechnology company created in 2011.